Johnson & Johnson

News

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.

News

Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.

News

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

News

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.